Catalogue

Background
Endothelial cell differentiation gene-2 (EDG2), or LPA1, receptor is a high affinity receptor for lysophosphatidic acid (LPA). EDG2 (LPA1), also known as lysophospholipid receptor A1, Vzg-1, mrec1.3 or GPCR26, like all other EDG receptors, couple multiple (3 or more) types of G proteins and transduce decreases in c[AMP]i through Gi and increases in [Ca2+]i by augmenting phospholipase C through Gq/11 and beta/gamma dimers and by induction of PI3 kinase, p125 FAK, phospholipase D by activating rho through G12/13. Human EDG2 (LPA1) is present in high levels on oligodendrocytes and certain human malignant T cell lines. EDG2 (LPA1) receptors (with EDG4) may play a role in protecting cardiomyocytes from apoptosis induced by hypoxia and andrenergic stimulation.

Synonyms: Blocking peptide for use in Western blotting with Anti-EDG2 (LPA1) (CT) (Cat. No. C174P)

Product

Product Form: Unconjugated

Formulation: Provided in solution at 1 mg/ml in phosphate buffered saline.

Concentration: See vial for concentration

Applications
For use with EDG2 (LPA1) (CT) polyclonal antibody (Cat. No. C174P).

Functional Analysis: Western Blotting

Storage
Product should be stored at -20°C. Aliquot to avoid freeze/thaw cycles

Product Stability: See expiration date on vial

Shipping Conditions: Ship at ambient temperature, freeze upon arrival

Caution
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. It may contain hazardous ingredients. Please refer to the Safety Data Sheets (SDS) for additional information and proper handling procedures. Dispose product remainders according to local regulations.This datasheet is as accurate as reasonably achievable, but our company accepts no liability for any inaccuracies or omissions in this information.